NRXP · NRX Pharmaceuticals, Inc. · Executive Compensation
$3.42
-0.06 (-1.59%)
At close · Sep 9
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$151.10M
Shares
43.30M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Javitt | Chairman and Chief Scientist | $630,198 |
| Richard Narido | Chief Financial Officer | $298,015 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jonathan Javitt | Chairman and Chief Scientist | $873,696 |
| Stephen Willard | Chief Executive Officer | $799,871 |
| Richard Narido | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Taylor | Class I director | Appointed | 2026-03-24 |
| Chaim Hurvitz | Class I director | Appointed | 2026-03-24 |
| Joseph M. Casper | Chief Operating Officer | Appointed | 2026-02-02 |
Key facts
CIK
1719406
CUSIP
629444209
13F (30d)
33 filings
33 filers
Visit website
Investor relations